arrow
M

Marie Sébert

universite paris cite
H指数:26
被引数:2,899

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Mesenchymal stromal cells drive immune escape in MDS and sAML through metabolic rewiring of NK cells

间充质基质细胞通过代谢重编程NK细胞驱动MDS和sAML中的免疫逃逸

Leukemia
IF13.4
2026-11-090
PRE
Ivosidenib monotherapy in IDH1 mutated myelodysplastic neoplasm/syndrome

伊沃斯登ib单药治疗IDH1突变性骨髓异常增生性肿瘤/综合征

Leukemia
IF13.4
2026-08-250
PRE
Splicing-associated network PAK1-CLK1/4-SRRM1 is a vulnerability to overcome chemoresistance in human and mouse acute myeloid leukemia

剪接相关网络PAK1-CLK1/4-SRRM1是人类和小鼠急性髓系白血病克服化疗耐药的易感靶点

2026-07-080
PRE
Characteristics and prognostic significance of myelodysplasia-related features in VEXAS syndrome

骨髓发育异常相关特征的特性和预后意义在VEXAS综合征中

Leukemia
IF13.4
2026-01-160
PRE
Inflammatory disorders in IDH-mutated myeloid neoplasms: Characteristics and response to IDH inhibitors

IDH突变髓系肿瘤中的炎症性疾病:特征及对IDH抑制剂的应答

2025-11-250
OAAI
Myeloid neoplasms risks for germline DDX41 pathogenic variants carriers

携带胚系DDX41致病性变异的髓系肿瘤风险

2025-10-030
PRE
Allogeneic hematopoietic stem cell transplantation in germline DDX41 mutated patients with myeloid malignancies

同种异基因造血干细胞移植在种系DDX41突变伴髓系恶性肿瘤患者中的应用

2025-09-110
OAAI
ESA PLUS LUSPATERCEPT (LUSPA) AFTER LUSPA FAILURE IN MDS OR MDS/MPN WITH RINGED SIDEROBLASTS (RS). A RETROSPECTIVE REAL-LIFE STUDY BY THE GFM

ESA联合Luspatercept(LUSPA)在伴有环状铁粒幼细胞的MDS或MDS/MPN患者中LUSPA治疗失败后的应用。由GFM进行的一项回顾性真实世界研究。

2025-09-010
OAAI
Oral decitabine and cedazuridine maintenance after haematopoietic stem-cell transplantation in very high-risk acute myeloid leukaemia or myelodysplastic syndrome (GFM-DACORAL-DLI): a multicentre, single-arm, phase 2 trial

口服地西他滨和西达佐利德维持治疗在极高危急性髓系白血病或骨髓增生异常综合征患者造血干细胞移植后的应用(GFM-DACORAL-DLI):一项多中心、单臂、II期临床试验

2025-08-070
PRE
IPSS-M risk and specific sex-associated somatic mutations predict response to ESA therapy in LR-MDS: building a new score

IPSS-M风险和特定性别相关的体细胞突变预测LR-MDS对ESA疗法的反应:构建一个新评分

Blood
IF23.1
2025-06-270
PRE
Prognostic significance of monocytic-like phenotype in patients with AML treated with venetoclax and azacytidine

单核细胞样表型在应用维奈克拉和氮杂胞苷治疗的AML患者中的预后意义

2025-04-210
OA
Prognostic Significance of Monocytic-like Phenotype in AML Patients Treated with Venetoclax and Azacytidine

单核细胞样表型在用Venetoclax和Azacytidine治疗的AML患者中的预后意义

BLOOD
IF23.1
2024-11-050
PRE
Cutaneous clonal mature plasmacytoid dendritic cell dermatosis in patients with myeloid neoplasms

髓系肿瘤患者的皮肤克隆成熟浆细胞样树突状细胞皮肤病

2024-06-141
OAAI
Targeting a lineage-specific PI3Kγ-Akt signaling module in acute myeloid leukemia using a heterobifunctional degrader molecule

使用异双功能降解剂分子靶向急性髓性白血病中的谱系特异性PI3Kγ-Akt信号模块

2024-05-302
PRE
Germline CHEK2 mutations in patients with myeloid neoplasms

髓系肿瘤患者的种系CHEK2突变

LEUKEMIA
IF13.4
2024-02-201
PRE